SCHEMBL2600494

SCHEMBL2600494

Cc1ccc(S(=O)(=O)N2C3CCCCCCC32)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.67
ALDH1A1 P00352 5/20 0.54
KDM4E B2RXH2 1/20 0.54
PKM P14618 3/20 0.53
POLB P06746 1/20 0.53
HTT P42858 1/20 0.53
CYP3A4 P08684 1/20 0.53
TSHR P16473 1/20 0.53
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 1/20 0.49
EPHX2 P34913 1/20 0.49
MCOLN3 Q8TDD5 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MMP2 P08253 1/20 0.49
PSEN1 P49768 2/20 0.48
PSEN2 P49810 2/20 0.48
APH1B Q8WW43 2/20 0.48
NCSTN Q92542 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL537069 0.98 ACHE (0.69) ACHEALDH1A1KDM4EPKMPOLB
SCHEMBL2690876 0.94 ACHE (0.74) ACHEALDH1A1KDM4EPKMPOLB
SCHEMBL13830631 0.86 ACHE (0.58) ACHEALDH1A1KDM4EPKMPOLB
SCHEMBL13812162 0.82 ACHE (0.68) ACHEALDH1A1KDM4EPKMPOLB
SCHEMBL27201918 0.80 ACHE (0.53) ACHEALDH1A1KDM4EPKMPOLB
SCHEMBL27201781 0.80 ACHE (0.56) ACHEALDH1A1PKMPOLBHTT
SCHEMBL13069242 0.80 ACHE (1.00) ACHEALDH1A1KDM4EPKMPOLB
SCHEMBL19392468 0.80 ACHE (1.00) ACHEALDH1A1KDM4EPKMPOLB
SCHEMBL13248930 0.80 ACHE (1.00) ACHEALDH1A1KDM4EPKMPOLB
SCHEMBL14538647 0.79 ACHE (0.86) ACHEALDH1A1KDM4EPKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163944-B2 Allylic oxidations catalyzed by dirhodium catalysts under aqueous conditions UNIVERSITY OF MARYLAND COLLEGE PARK (US) 2012-04-24 US disclosed
US-7662969-B2 Efficient aziridination of olefins catalyzed by dirhodium catalysts UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2010-02-16 US disclosed
US-20090093638-A1 Allylic Oxidations Catalyzed by Dirhodium Catalysts under Aqueous Conditions UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2009-04-09 US disclosed
US-20060030718-A1 Cobalt-based catalysts for the cyclization of alkenes UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030718-A1 Cobalt-based catalysts for the cyclization of alkenes PPOX, HCCS, ICOSLG ACHE 2913/4885ALDH1A1 3259/4885KDM4E 1717/4885
US-20090093638-A1 Allylic Oxidations Catalyzed by Dirhodium Catalysts under Aqueous Conditions CYP11B2, DHCR7, ZDHHC7 ACHE 2900/4885ALDH1A1 530/4885KDM4E 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.